Results 31 to 40 of about 205,639 (219)

Design and analysis strategies for robust microbiome ageing research

FEBS Letters, EarlyView.
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik, İsmail Güderer, Yi Wang, Tayyaba Alvi, Prasoon Pandey, Handan Melike Dönertaş   +5 more
wiley   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

Rapid Quantification of Ceftobiprole in Human Plasma and Cerebrospinal Fluid by LC-MS/MS and Its Application in Patients with Central Nervous System Infections

Molecules
Ceftobiprole is a fifth-generation beta-cephalosporin with high inter-individual pharmacokinetic variability in critically ill patients. However, data on its pharmacokinetics and central nervous system (CNS) penetration are limited.
Sabahat Ablimit, Wanzhen Li, Mengting Chen, Jing Zhang, Nanyang Li, Yaxin Fan, Muyassar Yasen, Mubarak Iminjan, Beining Guo   +8 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Novel Pathways of Oxidative and Nitrosative Inactivation of the Human MGMT Protein in Colon Cancer and Glioblastoma Cells: Increased Efficacy of Alkylating Agents In Vitro and In Vivo

Diseases
Background: O6-Methylguanine-DNA methyltransferase (MGMT) is a unique antimutagenic DNA repair protein that plays a crucial role in conferring resistance to various alkylating agents in brain tumor therapy.
Debasish Basak, Agm Mostofa, Hanumantha Rao Madala, Kalkunte S. Srivenugopal   +3 more
doaj   +1 more source

Partial depletion of plasminogen activator inhibitor‐1 decreases subcutaneous fat cell hypertrophy and liver cholesterol in high‐fat‐fed female mice

FEBS Letters, EarlyView.
Obesity raises blood levels of PAI‐1, a protein linked to metabolic dysfunction‐associated steatotic liver disease in people with obesity. In female mice fed a high‐fat diet, partially lowering PAI‐1 led to smaller subcutaneous fat cells and lower liver cholesterol, without changing body weight or insulin sensitivity.
Claudia E. Ramirez Bustamante, Robert Sharp, Pradip K. Saha, Elizabeth S. Anaya, Elizabeth L. Lieu, Evelyn L. de Groot, Pooja Patel, Mi Jeong Heo, Aaron R. Cox, Kang Ho Kim, Sean M. Hartig   +10 more
wiley   +1 more source

Hippocampal CaMKII-α β-hydroxybutyrylation induces memory deficits in mice with type 1 diabetes mellitus

Communications Biology
Memory loss is a manifestation of type 1 diabetes mellitus (T1DM)-induced brain damage resulting from hyperglycemia. However, the mechanism underlying T1DM-induced memory deficit remains largely unknown.
Hongchun Li, Rong Chen, Hongbo Wang, Jingwei Tian, Yinglan Zhao, Xiaobo Cen   +5 more
doaj   +1 more source

Pharmacokinetics, safety and population pharmacokinetics/pharmacodynamics analysis of meropenem-vaborbactam in Chinese healthy participants

Frontiers in Pharmacology
BackgroundMeropenem-vaborbactam is a fixed-dose β-lactam/β-lactamase inhibitor combination active against carbapenem-resistant Enterobacterales (CRE), especially Klebsiella pneumoniae carbapenemase (KPC)-producing CRE.
Wanzhen Li, Wanzhen Li, Qiong Wei, Mengting Chen, Mengting Chen, Xiaofen Liu, Xiaofen Liu, Beining Guo, Beining Guo, Yuancheng Chen, Qi Zhang, Wei Guan, Long Shen, Xiaohui Wang, Nanyang Li, Yan Chen, Yan Chen, Xin Li, Xin Li, Yingying Hu, Jing Zhang, Jing Zhang, Jing Zhang, Xiaojie Wu, Xiaojie Wu   +24 more
doaj   +1 more source

Preclinical species gene expression database: Development and meta-analysis

Frontiers in Genetics, 2023
The evaluation of toxicity in preclinical species is important for identifying potential safety liabilities of experimental medicines. Toxicology studies provide translational insight into potential adverse clinical findings, but data interpretation may ...
Caitlin Krause, Kinga Suwada, Eric A. G. Blomme, Kenneth Kowalkowski, Michael J. Liguori, Prathap Kumar Mahalingaiah, Scott Mittelstadt, Richard Peterson, Lauren Rendino, Andy Vo, Terry R. Van Vleet   +10 more
doaj   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source